Science Consulting in Diabetes GmbH, Neuss, Germany.
GECKO Institut, Hochschule Heilbronn, Germany.
J Diabetes Sci Technol. 2020 Mar;14(2):240-249. doi: 10.1177/1932296819867686. Epub 2019 Aug 5.
Integrated personalized diabetes management (iPDM) is a digitally supported therapeutic concept to improve patient-physician interaction to overcome the aspects of clinical inertia. Integrated personalized diabetes management can support decision making and improve therapeutic outcomes of suboptimally controlled persons with insulin-treated type 2 diabetes (T2D). In this paper, we report the results of an analysis of the PDM-ProValue study program on the effectiveness and perceived benefit of this approach, with a focus on how physicians used and assessed the digital tools provided for the iPDM process.
The study program included two 12-month, prospective, controlled, cluster-randomized multicenter trials. A total of 101 practices participated with 907 patients. Practices were cluster-randomized to an intervention group and a control group. Digital tools for data visualization and analysis applied were used. HCP were asked to assess the use, relevance, and usefulness of the tools.
A clear preference was stated for the visual overview over more statistically complex analyses. A total of 83% of the participants rated a high relevance of the "daily profile," 81% of the "total profile," and 68% the "risk illustrated by traffic light symbols" for the therapy decision. The overall iPDM process was very favorably rated with respect to structuredness and potential for personalized treatment and well accepted among health care professionals (HCP).
Embedding digital tools in a structured process (iPDM) were proved to provide a benefit for insulin-treated T2D patients and their physicians. These results offer insight for further development and improvement of the tools and add information on how to overcome clinical inertia.
整合个性化糖尿病管理(iPDM)是一种数字化支持的治疗概念,旨在改善医患互动,克服临床惯性的各个方面。整合个性化糖尿病管理可以支持决策,并改善接受胰岛素治疗的 2 型糖尿病(T2D)患者的治疗效果。在本文中,我们报告了 PDM-ProValue 研究项目中关于该方法有效性和感知益处的分析结果,重点关注医生如何使用和评估为 iPDM 过程提供的数字工具。
该研究项目包括两个为期 12 个月的前瞻性、对照、集群随机多中心试验。共有 101 家诊所参与,共纳入 907 名患者。诊所被集群随机分为干预组和对照组。应用了用于数据可视化和分析的数字工具。HCP 被要求评估工具的使用、相关性和有用性。
明确表示对可视化概述的偏好超过更具统计学复杂性的分析。共有 83%的参与者认为“日常概况”、81%的参与者认为“总概况”以及 68%的参与者认为“用交通灯符号说明的风险”对于治疗决策具有高度相关性。总体而言,iPDM 过程在结构化和个性化治疗的潜力方面得到了高度评价,并且在医疗保健专业人员中得到了很好的接受。
在结构化过程(iPDM)中嵌入数字工具被证明为接受胰岛素治疗的 T2D 患者及其医生提供了益处。这些结果为进一步开发和改进工具提供了见解,并提供了有关如何克服临床惯性的信息。